Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of Q3 and 9M/FY2024-25 Conference Call, which is to be ...
Shilpa Medicare Limited Corporate & Admin Office: “Shilpa House”, # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India Tel: +91-8532-238704, Fax: +91-8532-238876 Email: info@vbshilpa.com, Web: www.vbshilpa.com CIN: L85110KA1987PLC008739
Date: 04 February, 2025
To Corporate Relationship Department BSE Limited, 1st Floor, Rotunda Building, P.J. Towers, Dalal Street, Mumbai – 400 001.
To National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No.C/1, G Block Bandra Kurla Complex, Bandra (E) MUMBAI – 400 051.
Dear Sir/Madam,
Sub: Analysts/Investors Call Ref: Scrip Code: BSE - 530549/ Stock Symbol: NSE – SHILPAMED
Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of Q3 and 9M/FY2024-25 Conference Call, which is to be held on Tuesday, February 11, 2025 at 11:00 AM IST.
This is for your information.
Thanking you
For Shilpa Medicare Limited,
Ritu Tiwary Company Secretary & Compliance Officer
Shilpa Medicare Limited
Q3 and 9M FY25 Earnings Call
February 11, 2025, at 11:00 AM
Raichur, February 04, 2025: Shilpa Medicare Ltd. (BSE- 530549, NSE- SHILPAMED, ISIN: INE790G01031), will announce its financial results for the quarter and nine months ended December 31, 2024, on Monday, February 10, 2025. Following the announcement, the management of the Company will host an Earnings Call on Tuesday, February 11, 2025, at 11:00 AM IST.
Details of Earnings Conference Call
Day/Date
Time (IST)
Universal Access
Tuesday, February 11, 2025
11:00 AM
+91 22 6280 1107
+91 22 7115 8008
The number listed above is universally accessible from all networks and all countries
International Toll-Free Numbers USA
UK
Singapore
Hong Kong
18667462133
08081011573
8001012045
800964448
DiamondPass™ Link
Click here to join with DiamondPass™ (No Wait Time)
Management Representation:
Mr. Keshav Bhutada, Executive Director (SPLL)
Mr. Alpesh Dalal, Chief Financial Officer
Mr. Monish Shah, Head-Strategy and IR
Participants are requested to dial-in 10 minutes before the scheduled time
About Shilpa Medicare Limited (SML): Shilpa Medicare Limited (SML) is an integrated pharmaceutical group with business interests in niche Oncology & Non-oncology APIs, Peptides, Polymers, differentiated finished dosage formulations including orally dispersible films & transdermal patches along with carefully crafted biological portfolio.
The company also provides end-to-end CDMO services to global pharmaceutical companies across all its business segments based on its strong R&D and manufacturing capabilities backed by four R&D units and seven manufacturing facilities.
For further details, please get in touch with: Shilpa Medicare Ltd Mr. Monish Shah/ Dilip Kankani B: +91-9819865421/+91 8532238704 E: monish.shah@vbshilpa.com E: runjhun.jain1@in.ey.com / dilipkankani@vbshilpa.com
EY IR: Ms. Runjhun Jain / Ms. Sneha Salian M: +91-98207 20993/ +91-98194 30437
sneha2.salian@in.ey.com